Kiromic BioPharma, Inc. Presents at the 2018 Biotech Showcase
Houston, Texas, Jan. 10, 2018 – Kiromic Inc., today announced that it has attended and presented an overview of the company’s core-technology at the 2018 Biotech Showcase. Kiromic was represented at the event by Dr. Maurizio Chiriva (CEO). The conference was held during the course of one of the industry’s largest annual healthcare investor gatherings, on January 8th-10th in San Francisco, California.
About Kiromic Biopharma
Kiromic is a clinical-stage immunotherapy biopharmaceutical company with a breakthrough artificial intelligence drug discovery platform (KAI), and a focus on therapeutic development across multiple technology platforms; including cell therapy, TCR therapy, and CAR-T therapy, oral immunotherapy, and gene therapy.
Kiromic is committed to developing effective immunotherapeutics to improve outcomes and dramatically improve patient’s lives.
For more information, visit www.kiromic.com.
About Biotech Showcase
The Biotech Showcase™ is a networking and investor conference. The event provides private and public biotechnology and life sciences companies with an opportunity to meet with investors and pharmaceutical executives.
For more information, visit www.ebdgroup.knect365.com/biotech-showcase.